Iterum Therapeutics Plc
ITRM
Market Cap$22.82M
Close$
$-1.09
209.8% downside
Current Fair Value
209.8% downsideOvervalued by 209.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.82 Million |
|---|---|
| Enterprise Value | $10.60 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.96 |
| Beta | 2.25 |
| Outstanding Shares | 16,552,214 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.59 |
|---|---|
| PEG | 1.89 |
| Price to Sales | - |
| Price to Book Ratio | -0.99 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Iterum Therapeutics Plc
7 employeesIterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of peopl...